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Abstract

Article History:

Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disorder with few available
treatments. Mesenchymal stem cell therapy (MSCT), an innovative approach, has high therapeutic
potential when used to treat IPF. According to recent data, preconditioning of MSCs can improve
their therapeutic effects. Our research focuses on investigating the anti-inflammatory and antifibrotic effects of H2O2-preconditioned MSCs (p-MSCs) on mice with bleomycin-induced
pulmonary fibrosis (PF).
Methods: Eight-week-old male C57BL/6 mice were induced with PF by intratracheal (IT) instillation
of bleomycin (4 U/kg). Human umbilical cord vein-derived MSCs (hUCV-MSCs) were isolated and
exposed to a sub-lethal concentration (15 μM for 24 h) of H2O2 in vitro. One week following the
injection of bleomycin, 2×105 MSCs or p-MSCs were injected (IT) into the experimental PF. The
survival rate and weight of mice were recorded, and 14 days after MSCs injection, all mice were
sacrificed. Lung tissue was removed from these mice to examine the myeloperoxidase (MPO)
activity, histopathological changes (hematoxylin-eosin and Masson’s trichrome) and expression
of transforming growth factor beta 1 (TGF-β1) and alpha-smooth muscle actin (α-SMA) through
immunohistochemistry (IHC) staining.
Results: Compared to the PF+MSC group, p-MSCs transplantation results in significantly decreased
connective tissue (P < 0.05) and collagen deposition. Additionally, it is determined that lung tissue
in the PF+pMSC group has increased alveolar space (P < 0.05) and diminished expression of
TGF-β1 and α-SMA.
Conclusion: The results demonstrate that MSCT using p-MSCs decreases inflammatory and fibrotic
factors in bleomycin-induced PF, while also able to increase the therapeutic potency of MSCT in
IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive
inflammatory lung disorder with a not well-known
etiology. IPF is identified by high deposition of
extracellular matrix (ECM) proteins—mainly collagen—
in lung tissue.1 Despite its obscure etiology, cellular
damage and oxidative stress can activate inflammatory

processes and recruit immune cells into damaged lung
tissue.2-4 These uninterrupted inflammatory processes
result in provoking lung tissue and unintentional
expression of pro-inflammatory cytokines, such as TNF-α,
IL-1β, and IL-8.3 Along with reactive oxygen species,5
agents that facilitate apoptosis by inducing the activation
of caspases—specifically caspase-3—have been produced
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in lung tissue to impede reconstituting inflamed fibrosis
lung, therefore causing gradual loss of the lung tissue’s
proper function.6 Furthermore, pro-fibrotic cytokines,
such as transforming growth factor beta 1 (TGF-β1) and
alpha-smooth muscle actin (α-SMA), are overexpressed
by differentiated myofibroblasts during fibrosis process
in the lung of patients with PF and in animal models of
experimentally-induced fibrosis.7-9 Bleomycin (BLM) is
a chemotherapeutic medication, which can cause PF via
regulation of TGF-β1. Therefore, BLM has been used to
induce IPF in mice in many interventional studies.7-9
Despite accomplished extensive studies completed
to find a decisive treatment of IPF, no effective therapy
has been found to cure pulmonary fibrosis (PF) to date.
However, IPF is one of the main life-threatening diseases,
as expected survival of these patients after initial diagnosis
is approximately 3 years.10,11 Nowadays, cell therapy
using mesenchymal stem cells (MSCs)—with regards
to the immunomodulatory and regenerative effects of
these cells—is a novel or promising opportunity for the
treatment of diverse inflammatory, autoimmune and tissue
damage diseases, specifically lung diseases.12-17 MSCs
are recognized by their spindle‐shaped morphology and
expression of mesenchymal markers (such as CD44, CD73,
CD90, and CD105) but no hematopoietic markers (CD14,
CD34, and CD45). These cells have self-renewal capacity
and differentiation potential to various cellular lineages,
such as adipocytes, osteoblasts, and chondrocytes.18-21
Based on several studies, MSCs reduce tissue injury
through the production of mediators with anti-apoptotic,
anti-inflammatory and anti-fibrotic features.12,15,16 MSCs
can be obtained from fetal tissues, such as umbilical cord
blood and placenta, or adult tissues, like bone marrow and
adipose tissue.22 Because they have a longer telomere, fetal
tissue-isolated MSCs have higher proliferation capacity
than that of adult tissue-MSCs.5 The umbilical cord, as
a rich source of MSCs, is readily available and contains
more MSCs than other tissues.23,24
According to previous studies, anything that increases
the migration ability and survival of MSCs results in a more
effective treatment with stem cell therapy. Vital properties
of transplanted stem cells—such as survival, migration,
and tissue repair capacity—are influenced dramatically by
in vitro preconditioning of MSCs. Widespread studies have
been accomplished regarding in vitro preconditioning
on MSCs, but there is little information provided that
investigate the effects of preconditioning of these cells
in experimental animal models.14,25-30 In the present
study, the anti-inflammatory and anti-fibrotic effects of
H2O2 preconditioned hUCV-MSCs were evaluated in a
bleomycin-induced PF mice model.
Materials and Methods
Animals
Twenty-eight male mice of the C57BL/6 strain were
purchased from Pasture Institute of Iran (Tehran, Iran) and

kept in an animal house under standardized conditions.
In the time of experiments, mice were 6-8 weeks-old with
average weight 20-30 g. The mice were transported to the
laboratory for acclimation to the environment 72 h prior
to the start of the experiment.
Induction of PF and grouping
Experimental PF was induced by bleomycin under
anesthesia, as previously mentioned.8,31 The mice were
classified into four groups (n = 7). One group received
sterile PBS intratracheal (IT) injection, which was
considered as a control group (Ctrl). PF group was injected
with bleomycin (4 U/kg, suspended in 50 µL sterile PBS,
IT). The other treatment groups of mice include the
PF+MSC group, which received 2×105 hUCV-MSCs by
intratracheal injection 1 week after bleomycin injection,
while the PF+pMSC group received 2×105 preconditioned
hUCV-MSCs intratracheally.
Isolation, culture, and expansion of hUCV-MSCs
Before participating in the study, informed consent was
completed by pregnant women. Umbilical cords were
collected from cesarean operations within the healthy
term (38-40 weeks) and held in Hanks balanced salt
solution buffer containing 300 μg/mL streptomycin, 300
U/mL penicillin, and amphotericin B (1%) (Invitrogen
Gibco); then UCs were transferred to the laboratory. The
UC vein (UCV) was washed twice with Hanks balanced
salt solution and loaded with collagenase IV (0.1%)
(Invitrogen Gibco), then the ends of UCV were clamped
and incubated (37°C, 5% CO2, 20 min). The segregated
cells were rinsed with Dulbecco’s Modified Eagle’s media
with low glucose (DMEM-LG) (Invitrogen Gibco) and
centrifuged at 1500 RPM for 15 min. The cell pellets were
suspended and cultured in DMEM-LG containing 15%
fetal bovine serum (FBS) (Gibco, USA), 100 U/mL of
penicillin, and 100 μg/mL of streptomycin, then incubated
(37°C and 5% CO2). Initial media was replaced after 48
hours and non-adherent cells were omitted. Thereafter,
this was performed every 48 or 72 hours. After achieving
80-90% confluence, MSCs were incubated with trypsin
0.05% (Sigma, USA) and 0.02% EDTA for new passage
and were cultured until passage 4.
Characterization of hUCV-MSCs by flow cytometry
analysis
MSCs at the fourth passage were trypsinized, washed
using phosphate buffer saline (PBS) and resuspended in
PBS containing FBS (1%). A 100 μL aliquot of suspended
MSCs was incubated for 45 minutes at 4°C with one of
the following anti-human monoclonal antibodies (mAb):
phycoerythrin (PE)-conjugated CD105, CD34, and
CD73, or fluorescein isothiocyanate (FITC)-conjugated
CD45 (BioLegend, USA). In addition, the mouse
isotypic antibodies, including PE-IgG1j and FITC-IgG1j
(BioLegend, USA), were utilized as control. After labeling
Advanced Pharmaceutical Bulletin, 2020, Volume 10, Issue 1
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of cells, they were evaluated using BD FACS Calibur™
flow cytometer (BD, USA) and analyzed using Flow Jo 7.6
Software.
Characterization of hUCV-MSCs by differentiation
assay
Human UCV-MSCs differentiation abilities into osteocyte
and adipocyte lineages were examined at second passage.
Osteogenic differentiation
MSCs were cultured at a density of 1×104 cells/well in
24-well plates (SPL, Korea) and incubated at 37°C. After
24 hours, osteogenic differentiation media containing
glycerol phosphate (10 mM), dexamethasone (100 mM)
and ascorbic acid‐2 phosphate (5 g/mL) were added to
cells every 72 hours for 3 weeks. After fixing the cells with
4% paraformaldehyde, Alizarin Red S staining utilized for
detecting the mineralization in these cells.
Adipogenic differentiation
1.5 × 104 hUCV-MSCs/well were seeded in 24-well
plates (SPL, Korea) and incubated at 37°C for 24
hours. Adipogenic differentiation media containing
indomethacin (100 mM), 3‐isobutyl‐methylxanthine (0.5
mM), dexamethasone (250 mM) and insulin (5 mM) were
added to cells every 3 days and incubated at 37°C for 2
weeks. After fixing the cells with 4% paraformaldehyde,
Oil Red O staining utilized for determination of adipose
vacuoles in these cells.
Preconditioning of hUCV-MSCs with H2O2
MSCs were preconditioned with 15 μmol H2O2 for
24 hours, as previously reported.27 This non-toxic
concentration of hydrogen peroxide (15 μmol) induces a
protective influence on MSCs against the lethal dose of
H2O2 (300 μmol).

Transplantation of hUCV-MSCs to experimental models
(treatment procedure)
One week after bleomycin injection, the mice were
euthanized, and hUCV-MSCs were prepared for
administration to Mice. Both the hUCV-MSCs and H2O2
preconditioned hUCV-MSCs (p-MSC), at passage 4 with
a concentration of 2×105 cell/mouse, were suspended in
50 µL sterile PBS and administered intratracheally. The
control groups received only PBS in the treatment time.
The survival rate and weight of mice were recorded every
day, and mice were sacrificed 14 days after the treatment.
Lung tissues of the mice were removed promptly, shared
in several parts, fixed in formalin for histopathological
and immunohistochemical (IHC) examinations or frozen
at -70°C in order to investigate MPO enzyme activity.
Design of study is demonstrated in Figure 1.
Histopathological examination
Formaldehyde-fixed (10% buffered formaldehyde) lung
tissues were embedded in paraffin (5 μm) and stained
with hematoxylin-eosin (H&E) to investigate the volume
of alveolar space and connective tissue. In addition,
Masson’s trichrome was applied to evaluate collagen
deposition and connective tissue mass. The lung tissue
sections were examined using the light microscopy at
×100 and ×400 magnifications. Our histologist colleague
(MJ.R) was blinded to each group and performed the
histopathological evaluation of lung sections. Moreover,
in order to exactly investigate the histopathological
changes, the volume of the alveolar space and connective
tissue in all of the experimental groups were assessed
applying morphometric analysis (graticule checkerboard
18×kpl-w12.5).8,31
IHC examination
5-μm sections were obtained from paraffin-embedded

Figure 1. Study design for pulmonary fibrosis induction and treatment procedure. PF: pulmonary fibrosis, BLM: bleomycin, IT: intratracheally,
Ctrl: control, MSC: mesenchymal stem cell, pMSC: preconditioned MSC, MPO: myeloperoxidase, H&E: hematoxylin-eosin, IHC:
immunohistochemistry.
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lung samples and immunostained for TGF-β1 and α-SMA
as fibrosis biomarkers. Briefly, samples were deparaffinized
after the hydration, and antigen retrieval buffer was used
for 40 minutes. Endogenous peroxidase was quenched
with 0.1% hydrogen peroxide for 15-20 minutes. The
samples were blocked using serum-free protein (Sigma
Aldrich), then incubated with polyclonal antibodies of
anti-mouse TGF-β1 (Santa Cruz Biotechnology (SC146), 1:200 in PBS) and anti-mouse α-SMA (Abcam (ab5694), 1:200 in PBS) overnight. Following washing with
PBS, sections were detected with a sheep anti-rabbit IgG
secondary antibody, followed by a peroxidase polymer
and a solution of 0.1% 3, 3-diaminobenzidine (DAB)
and 0.02% H2O2. Finally, all the slides were stained with
hematoxylin to detect the nucleus of the cells.32-34
Myeloperoxidase (MPO) enzyme activity
Neutrophil accumulation within the lung tissues was
investigated by measuring the tissue MPO activity that
was described previously.6,35 Frozen tissue samples were
thawed at 4°C, then the tissues were homogenized in
20 mmol/L phosphate buffer (pH 7.4) and centrifuged
(13 000 × g, 10 min, 4°C). The obtained pellet was
resuspended with 0.5% hexadecyl trimethyl ammonium
bromide (Sigma-Aldrich) in 50 mmol/L phosphate buffer
(pH 6.0). Freeze-thaw cycles were done on the suspension
four times, followed by sonication. The samples were
recentrifuged (13 000 × g, 8 min, 4°C). MPO activity in the
resulting supernatant was measured using TMB for ELISA
at 405 nm. The results were reported as the absorbance
per mg of lung tissue weight (A°/mg).
Statistical analysis
Data was analyzed applying Graph Pad Prism 5 software.
All data was represented as a mean ± standard deviation
from the total number of mice in this study. Normality
of all data has been checked with Kolmogorov-Smirnov
normality test and differences between groups were
analyzed by one-way ANOVA and Tukey post test. P <
0.05 was demonstrated statistical significance.
Result and Discussion
Characterization of human UCV-MSCs by flow
cytometry analysis and differentiation assay
MSCs at passages two were analyzed with regard to the
high expression level of the mesenchymal markers (CD73
and CD105) and lack of expression of the hematopoietic
markers (CD34 and CD45) (Figure 2). In addition,
differentiation potency of these cells is demonstrated by
staining osteocytes and adipocytes with Alizarin Red S
and Oil Red O, respectively (Figure 3).
Survival and weight monitoring
The survival rate in all mice is similar between experimental
groups (data not shown). All mice were sacrificed at the end
of the experiment time (21 d) to perform histopathological

Figure 2. Characterization of human umbilical cord vein-derived
mesenchymal stem cells (hUCV-MSCs) by flow cytometry analysis shows that
these cells express high levels of CD73 and CD105 (mesenchymal markers)
and low levels of CD34 and CD45 (hematopoietic markers).

Figure 3. Characterization of human umbilical cord vein-derived
mesenchymal stem cells (hUCV-MSCs) by differentiation assay shows that
these cells can differentiate into adipocytes and osteocytes..

and immunological investigations. In addition, the results
of mice weight monitoring demonstrate no significant
difference between PF and treated groups (PF+MSC,
PF+pMSC) (data not shown).
Histopathological findings
The results of H & E staining at day 21 show a significant
decrease of alveolar space and increase of connective tissue
in mice receiving bleomycin (PF group), in comparison
to the negative control group (Ctrl) (P < 0.001). In
addition, infiltration of inflammatory cells, fibroblasts,
and consequent diffuse fibrosis confirmed the induction
of PF using BLM. In the group treated with hUCV-MSCs
(PF+MSC) and preconditioned MSCs (PF+pMSC),
the alveolar space is significantly increased (P < 0.001),
while the connective tissue is significantly lower
compared to the positive control group (PF) (P < 0.001).
Also, compared to the PF+MSC group, preconditioned
MSCs transplantation results in significantly decreased
connective tissue (P < 0.05) and increased alveolar space
(P < 0.05) (Figure 4).
In addition, Masson’s trichrome was applied to evaluate
the ECM macromolecules, such as collagen deposition.
The results of trichrome staining at day 21 show a
considerable increase of the collagen deposition (blue
color) in the PF group in compared to the Ctrl group. In the
Advanced Pharmaceutical Bulletin, 2020, Volume 10, Issue 1
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Figure 4. Microscopic analysis of lung sections after H&E staining. Compared to the pulmonary fibrosis group (PF), MSCs and preconditioned MSCs injection
increased alveolar space and reduced connective tissue (P < 0.001). Also p-MSCs transplantation results in significantly decreased connective tissue (P < 0.05)
and increased alveolar space (P < 0.05) in compared to the MSC group. H&E: hematoxylin-eosin, Ctrl: control, PF: pulmonary fibrosis, PF+MSC: treated group by
hUCV-MSCs, PF+pMSC: treated group by preconditioned hUCV-MSCs, (Magnification 100× and 400×). Values are expressed as mean ± SE (n =7). (*** P < 0.001,
** P < 0.01, * P < 0.05).

groups treated by hUCV-MSCs (PF+MSC), and especially
preconditioned MSCs (PF+pMSC), a remarkable decrease
of collagen deposition compared to the positive control
group (PF) is observed (Figure 5).
Immunohistochemical analysis of TGF-β1 and α-SMA
expression
According to IHC staining results, there is a high expression
of the TGF-β1 and a-SMA protein in the parenchyma areas
of lung tissues from PF group compared to the negative
control (Ctrl) group. However, the group administered

with hUCV-MSCs (PF+MSC) and preconditioned MSCs
(PF+pMSC) show a remarkable decrease of the TGF-β1
and a-SMA protein expression compared to the positive
control group. In addition, α-SMA expression is mainly
localized in the pulmonary vessel walls in the negative
control (Ctrl) group, whereas in the PF group was localized
in the parenchyma of fibrotic areas (Figures 6 and 7).
MPO enzyme activity assay
MPO has been known as a valuable biomarker of lung
inflammation and injury. MPO enzyme activity confirms

Figure 5. Microscopic analysis of lung sections after Masson’s trichrome staining. Compared to the pulmonary fibrosis group (PF), MSCs and especially
preconditioned MSCs injection reduced collagen deposition (blue color) and extracellular matrix. Ctrl: control, PF: pulmonary fibrosis, PF+MSC: treated group by
hUCV-MSCs, PF+pMSC: treated group by preconditioned hUCV-MSCs, (Magnification 100× and 400×).
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Figure 6. Representative images of TGF-β1 expression and localization in the lung sections after IHC staining. Compared to the pulmonary fibrosis group
(PF), MSCs and especially preconditioned MSCs injection considerably decreased TGF-β1 protein expression in the parenchyma areas of lung tissues. IHC:
Immunohistochemistry, Ctrl: control, PF: pulmonary fibrosis, PF+MSC: treated group by hUCV-MSCs, PF+pMSC: treated group by preconditioned hUCV-MSCs,
(Magnification 100× and 400×).

Figure 7. Representative images of α-SMA expression and localization in the lung sections after IHC staining. Alpha-SMA expression was mainly localized in the
pulmonary vessel walls in the negative control (Ctrl) group, while in the pulmonary fibrosis (PF) group was localized in the parenchyma of fibrotic areas. Compared
to the pulmonary fibrosis group (PF), MSCs and especially preconditioned MSCs injection considerably decreased α-SMA protein expression in the parenchyma
areas of lung tissues. IHC: Immunohistochemistry, Ctrl: control, PF: pulmonary fibrosis, PF+MSC: treated group by hUCV-MSCs, PF+pMSC: treated group by
preconditioned hUCV-MSCs, (Magnification 100× and 400×).

the oxidative stress following BLM exposure and extent/
activation of inflammatory cells, such as neutrophils or
monocyte/macrophages in lung tissue.6 Accordingly,
Figure 8 demonstrates a five-fold increase in MPO
activities following BLM injection (PF group) as compared
to the negative control (Ctrl) group (P < 0.001). HUCVMSCs and preconditioned MSCs significantly decrease
MPO activities in the treated groups (PF+MSC (P < 0.01)
and PF+pMSC (P < 0.001)) as compared to the PF group.
Yet, no significant difference is observed between the two
treated groups.
PF is a progressive inflammatory and fibrotic lung
disorder, distinguished by overexpression of proinflammatory cytokines, reactive oxygen species and
pro-fibrotic cytokines, such as TGF-β1. Deposition of
ECM proteins, like collagen, aggravates the lung injury.
Moreover, the connective tissue will reduce the alveolar
space of the lung.1,8,31 To date, there is no useful cure for
PF. The only possible treatment approach for PF patients

at the end stage of the disease is lung transplantation.
However, PF is a life-threatening disease.36 Regarding
fibrosis immunopathogenesis, many previous studies
have revealed that MSCs, because of anti-inflammatory
and anti-fibrotic effects, could be potentially helpful for
the treatment of PF.8,36-39 Nevertheless, the inappropriate
environment of inflammatory and fibrotic tissue with
large amounts of pro-inflammatory cytokines, reactive
oxygen species, and many other harsh factors will diminish
the potency of cell therapy after transplantation.40-42
Some studies reported that in vitro preconditioning of
MSCs could promote essential features, such as survival,
migration and tissue repair capacity of transplanted stem
cells against harsh microenvironment.14,25,27-29 Regarding
the previous studies and the necessity of conducting in
vivo study,27,29 our work is among the few studies ever
done in this field on experimental animal models.14,30
In the current study, we are the first to evaluate the
anti-inflammatory and anti-fibrotic effects of H2O2
Advanced Pharmaceutical Bulletin, 2020, Volume 10, Issue 1
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Nouri et al29 noted that preconditioning of MSCs with 20
μM H2O2 (12 h) improved cell resistance against lethal
microenvironment via HIF-1α overexpression. Also,
Bashiri et al27 demonstrated that preconditioning with
15 μM (24 hours) has better protective effects than other
concentrations of H2O2. For this reason, we used 15 μM
(24 hours) for preconditioning of the hUCV-MSCs in the
present study.

Figure 8. Effect of hUCV-MSCs and preconditioned hUCV-MSCs on
myeloperoxidase (MPO) activity in lung tissue. The results were reported as
the absorbance per mg of lung tissue weight (OD/mg). Values are expressed
as mean ± SE (n = 7). MPO activities following BLM injection (PF group)
were significantly higher than the control (Ctrl) group (P < 0.001). Therefore,
hUCV-MSCs (P < 0.01) and preconditioned MSCs (P < 0.001) demonstrated a
significant decrease of MPO activities in the treated (PF+MSC and PF+pMSC)
groups as compared to the PF group. However, there was no significant
difference between the two treated groups. (*** P < 0.001, ** P < 0.01)

preconditioned hUCV-MSCs in mice with PF induced
by bleomycin. H2O2 preconditioned cells show increased
survival, proliferation and grafting rate. Upregulation of
several anti-apoptotic proteins, growth factors, cytokines
and activation of some signaling pathways is involved
in vitro H2O2 effects, whereas there are few pieces of
information in vivo investigations in this field.27,29 Results
of this work suggest that intratracheal transplantation of
H2O2 preconditioned hUCV-MSCs are more effective in
decreasing connective tissue and collagen deposition and
increasing alveolar space in the experimental PF model
(Figures 4 and 5). In addition, H2O2 treated MSCs are more
effective in reducing TGF-β1 and α-SMA expression in
fibrotic lung tissue (Figures 6 and 7). However, there was
no significant difference between the H2O2-treated MSCs
and PF+MSC group in MPO enzyme activity (Figure 8).
Several studies examined the effects of the route of
MSC administration in animal PF. These studies showed
that local (IT) and systemic (IV or IP) injection of MSCs
attenuate lung injury and fibrosis.14,38 Nevertheless, local
injection requires a lesser amount of these cells and
reduces systematic administration complications.38,43,44
Therefore, in this study, 2×105 H2O2 preconditioned
hUCV-MSCs (PF+pMSC) and the same dose of untreated
hUCV-MSCs (PF+MSC) was injected intratracheally (IT)
into the C57BL/6 mice with bleomycin-induced PF. In
many previous studies in this field, MSC transplantation
was conducted within the first 2 weeks after BLM
injection. In the Moradi et al8 study, administration of
MSCs was done 15 min after BLM injection, whereas in
this work administration of these cells performed on the
seventh day after PF induction. Similar to the results of
previous studies, our results show that MSCT in the initial
or inflammatory phase can have useful effects, rather than
the fibrotic phase of PF.14,38,45 There are a few studies to
address the involved mechanisms of H2O2 preconditioning.
78
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Conclusion
The results of this study reveal that in vitro preconditioning
of MSCs with a sub-lethal concentration of H2O2 can
improve the therapeutic potency of MSC therapy in
IPF and diminish inflammatory and fibrotic factors in
bleomycin-induced PF. Nevertheless, further examinations
should be conducted to evaluate the anti-inflammatory
and anti-fibrotic effects of H2O2 preconditioned MSCs in
other experimental models of diseases. In addition, future
studies are required to investigate the cytoprotective
mechanisms involved during the in vitro preconditioning.
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